Quantitative Assessment of Hypoglycaemia-Induced EEG changes in Type 1 Diabetes Subjects by Rubega, Maria
Maria Rubega
Quantitative Assessment of
Hypoglycaemia-Induced EEG changes in
Type 1 Diabetes Subjects
Tesi di laurea magistrale
Relatore: Prof. Giovanni Sparacino
Correlatrice: D.ssa Chiara Fabris
Università degli Studi di Padova
Facoltà di Ingegneria
Dipartimento di Ingegneria dell’Informazione
Ottobre 2013

Ai miei genitori.

Abstract
Type 1 diabetes (T1D) is a chronic disease that causes a complete insulin
deficiency. Thus, patients affected by T1D have to undergo a suitable therapy
(comprising exogenous insulin administration) and to monitor, as tight as possible,
their blood glucose concentration (BG) levels, in order to avoid dangerous hyper-
(BG > 180 mg/dl) and hypoglycaemic (BG < 70 mg/dl) events. In particular,
while hyperglycaemia is related with the development of long term complications,
hypoglycaemia is an even more severe condition, since it may rapidly progress into
come, also without subject awareness, especially at night.
Excursions of glycaemia outside the normal 70-180 mg/dl range influence several
vital functions and signs. In particular, in the last years, the occurrence of the elec-
troencephalogram (EEG) changes related to hypoglycaemia has been investigated
by many researchers, highlighting an increase in the low frequency EEG bands
during the transition to this condition. This suggested the possibility of using the
brain as a biosensor to detect hypoglycaemia in real-time from suitable EEG signal
processing.
The aim of the present thesis is to quantitatively assess how hypoglycaemia influ-
ences EEG features by analizing 19 EEG recordings and sparse BG data collected in
parallel in T1D subjects during an insulin-induced hypoglycaemia experiment (data
were kindly provided by Hypo-Safe A/S, Odense University Hospital, Sydvestjysk
Sygehus Esbjerg, Denmark). Three 1-hour time-intervals corresponding to hyper-,
eu- and hypo-glycaemia, respectively, were then selected from BG data, and the
P3-C3 EEG channel was processed through several techniques based on spectral
analysis, to investigate if specific EEG features change during the transition from
eu- to hypo-glycaemia. In particular, lots of different methods found in literature
have been considered, from well-established classic methods (such as the power
spectral density computation) to more recent ones (such as the use of a reactivity
index), in order to assess the different trend of the EEG time-series in hypo- and
in eu-glycaemia. Promising results have been obtained with all considered meth-
ods, proving the possibility to properly characterize the hypoglycaemic condition
from retrospective analysis of the EEG signal and encouraging the development of
systems to detect or prevent hypoglycaemic events from the on-line EEG signal
processing.
As far as the thesis structure is concerned, Chapter 1 first introduces the diabetes
pathology and its implication on the EEG signal, with a detailed description of
methods and results of literature works dealing with hypoglycaemia-related EEG
changes. In Chapter 2, the data base considered in the study is presented. In
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Chapter 3 we analyse the EEG in eu- and hypo-glycaemia, by indicators computation
in the frequency domain. Chapter 4 focuses on a possible improvement of the
methods presented in Chapter 3, based on the individualization of the EEG bands.
In Chapter 5 we discuss the use of a new reactivity index measure to detect
hypoglycaemia in real time. In Chapter 6, conclusions that can be drawn from the
study are summarized, with some indications for further margins of investigation.
Sommario
Il diabete di tipo 1 (T1D) è una malattia cronica che provoca mancanza completa
di insulina.
Per questo, i pazienti che soffrono di T1D devono seguire una terapia mirata (che
consiste di dosi esogene di insulina) e devono monitorare, più spesso possibile, il
loro livello di concentrazione di glucosio nel sangue per evitare pericolosi eventi
iper- (BG > 180 mg/dl) e ipo-glicemici (BG < 70 mg/dl). In particolare, mentre
l’iperglicemia è legata allo sviluppo di complicazioni a lungo termine, l’ipoglicemia è
addirittura una condizione peggiore, perchè può presentarsi improvvisamente senza
che il paziente ne sia cosciente, soprattutto di notte.
Valori di glicemia fuori dall’intervallo normale di 70-180 mg/dl influenzano alquanto
le funzioni vitali. In particolare, negli ultimi anni, è stato studiato da molti ricerca-
tori come il segnale elettroencefalografico cambia con l’ipoglicemia, evidenziando
un aumento nelle bande EEG alla basse frequenze durante il passaggio a questa
condizione. Ciò ha suggerito di usare il cervello come biosensore per individuare
episodi ipoglicemici in real-time con i metodi disponibili di elaborazione del segnale
EEG.
Lo scopo di questa tesi è di valutare quantitativamente come l’ipoglicemia influenza
le caratteristiche dell’EEG, analizzando 19 tracciati EEG e i corrispettivi dati
BG registrati in parallelo in soggetti T1D durante un esperimento di ipoglicemia
indotta (i dati sono stati gentilmente messi a disposizione da HypoSafe A/S, Odense
University Hospital, Sydvestjysk Sygehus Esbjerg, Denmark). Tre periodi di un’ora,
corrispondenti rispettivamente a iper- eu- e ipo-glicemia, sono stati selezionati dai
dati BG, e il canale P3-C3 è stato elaborato con diverse tecniche basate sull’analisi
spettrale per scoprire se specifiche caratteristiche del segnale EEG cambiano duran-
te il passaggio da eu- a ipo-glicemia. In particolare, sono stati considerati molti
metodi differenti trovati in letteratura, da metodi classici ben consolidati (come
il calcolo della potenza spettrale) ai più recenti (come l’uso del reactivity index),
per individuare i diversi andamenti del segnale EEG in ipo- iper- ed eu-glicemia.
Sono stati ottenuti risultati promettenti con i metodi considerati, dimostrando la
possibilità di caratterizzare efficacemente la condizione di ipoglicemia attraverso
l’analisi retrospettiva del segnale EEG e incoraggiando lo sviluppo di sistemi per
individuare o prevenire eventi ipoglicemici dall’elaborazione del segnale EEG in
tempo reale.
Per quanto riguarda la struttura della tesi, il Capitolo 1 introduce la patologia
del diabete e le sue implicazioni sul segnale EEG, con una descrizione dettagliata dei
metodi e dei risultati presenti in letteratura. Nel Capitolo 2, sono presentati i dati
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reali di pazienti diabetici elaborati in questo studio. Nel Capitolo 3 si analizza il
segnale EEG in eu- e ipo-gicemia tramite l’applicazione di indicatori ipoglicemici nel
dominio della frequenza. Il Capitolo 4 si concentra su un possibile miglioramento dei
metodi presentati nel Capitolo 3, metodi basati sulla personalizzazione delle bande
EEG. Nel Capitolo 5 si tratta del reactivity index per individuare l’ipoglicemia in
tempo reale. Nel Capitolo 6, sono sintetizzate le conclusioni derivanti da questo
studio con alcune indicazioni per futuri miglioramenti.
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Chapter 1
The diabetes pathology and its
influence on the EEG signal
1.1 Diabetes, socio-economical impact and therapy
Diabetes is one of the most important and diffused chronic diseases [1]. About
366 million people worldwide were estimated to have diabetes in 2011 and if these
trends goes on, 522 million people will have diabetes in 2030 [2]. The largest increase
will take place in the developing economies, because diabetes has grown together
with rapid cultural and social changes, ageing populations, increasing urbanisation,
dietary changes, reduced physical activity and others unhealthy behaviours [2].
In Figure1.1, the prevalence of diabetes in 2011 and its estimation in 2030 by the
different world regions are shown in Figure1.1a, while Figure1.1b represents the
prevalence of people with diabetes by age and sex in 2011[3].
(a) Comparison of prevalence of diabetes by IDF
region
(b) Prevalence of people with diabetes by age
and sex
Figure 1.1: 2011 Diabetes diffusion [3]
The pathology of diabetes appears when the body is not able to produce enough
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or efficacious insulin1 [4]. In particular, there are two principal types of diabetes:
• type 1 diabetes (T1D);
• type 2 diabetes (T2D);
Starting from the second pathology, T2D, also called insulin-independent dia-
betes, is mostly due to a poor diet, increasing age, physical inactivity or family
history of diabetes, and causes a resistance to insulin developed by body tissues.
This pathology mainly occurs in obese adults and, at the present time, affects
about the 90-95% of diabetic people [2]; however, the number of T2D subjects
will rapidly increase next years. T2D patients don’t usually need daily doses of
insulin to survive but they typically require to improve their diet and to increase
their physical activity, in order to enhance their conditions. T1D, on the other
hand, is due to an insulin production deficiency, and it’s caused by a progressive
autoimmune destruction of the pancreatic beta-cells that make the hormone insulin.
Normally, the body immune system fights off foreign invaders such as bacteria
or viruses, but for unknown reasons, the immune system attacks various cells in
the body, causing a complete deficiency of the insulin hormone. [5]. The hormone
insulin has an anabolic function, it helps sugar to enter the body cells that exploit
it as energy source [6]. So thanks to insulin, the amount of sugar in the blood
decreases. But too much insulin causes hypoglycaemia (low blood sugar level),
otherwise its (complete or partial) deficiency leads to diabetes [7].
Type 1 diabetes is also called insulin-dependent diabetes and it usually occurs in
children or young adults. It currently affects about 5-10% of the whole diabetic
population [7], but, the number of people developing T1D is increasing each year,
probably because of changes in environmental risk factors, early events in the womb,
diet early in life or viral infections[3]. Since T1D progresses into a complete insulin
deficiency, people affected by this pathology need an insulin therapy (insulin shots
to use glucose from meals[1]) to control their blood glucose concentration levels.
Despite the increased use of insulin analogues and pumps for continuous insulin
infusion, however, it is very difficult to replace the insulin need exactly and, as a
result, blood glucose concentration often exceeds the normality range towards hypo-
(<70 mg/dl) or hyper- (>180 mg/dl) glycaemia. Both these conditions are related
to the development of complications from diabetes, but, while hyperglycaemia
causes long-term complications, such as nephropathy, retinopathy and cardiovascu-
lar diseases, hypoglycaemia may rapidly progress into coma, also without subject
awareness, especially at night. For this reason, T1D subjects should be monitored
in real-time, in order to prevent the occurrence of dangerous hypo events. In
this context, the introduction of minimally-invasive, if not non-invasive, sensors
proposed in the 2000’s to continuously monitor glycaemia can be of significant help
in the timely detection, and even prevention, of dangerous hyper-/hypo-glycaemic
events [8].
1The insulin is the most important energy body regulator. It is injected into the blood because
of an increase in blood glucose. It allows the glucose absorption and storage in the liver, muscle
and adipose tissue.
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1.2 The EEG signal
The EEG is the recording of brain electrical activity made along the scalp
in standard locations (according, for example, with the 10/20, 10/10 or 10/5
international system) [9]. Despite the high temporal resolution, EEG systems are
characterized by a poor spatial resolution, and artefacts and noise typically affect
the EEG recordings.
The main features of EEG time-series are:
• frequency band 1-70 Hz;
• amplitude tens of microV;
• it’s a stationary signal2 at times;
• it’s not periodic but often has a dominant rhythm.
In the frequency domain the EEG signal can be divided in different frequency
ranges (bands), as described in the following:
• Delta is from 1 to 4 Hz. This frequency range is characterized by high-
amplitude waves. It’s recorded frontally in adults and posteriorly in babies.
• Theta is from 4 to 8 Hz. This band is usually found in children and it
represents a meditative and relaxed state in adults.
• Alpha is from 8 to 13 Hz. This waveform is seen in both posterior regions
of the brain and it appears with closing eyes and it decreases during mental
efforts and opening eyes.
• Beta is from 13 to 30 Hz. This frequency range is seen in both sides of the
brain and it’s characterized by low-amplitude waves. It represents thinking,
active concentration and movements.
• Gamma is from 30 to 100 Hz. It illustrates the linking between neurons, in
fact it’s probably responsible of motor and cognitive functions.
In the clinic practice, EEG time-series are used to identify and quantify deficit of
the brain activity, detect epilepsy, monitor the patient during anesthesia, study
sleep stages and study the effect of medication/drugs/meditation.
Since glucose represents an essential substrate for brain functioning, hypo-
glycaemia and the consequent neuroglycopenia may result in an altered cerebral
activity. In fact, while some tissues, such as muscle, liver and kidneys, can store a
certain amount of glycogen 3 as a reserve to draw upon if blood sugar drops too
low, the brain has no reserves and it entirely depends on the blood for the glucose
supply4. Therefore, the brain is the first organ to be affected by hypoglycaemia and
the decrease of cerebral functioning consequent to this condition can be investigated
through suitable analysis of the electroencephalogram signal (EEG).
2A signal is stationary if its statistical behavior is invariant after a translation of the time axis.
3Glucose is converted in glycogen to become a form of energy storage in humans.
4Glucose arrives to neurons and other nerve cells by diffusion thanks to capillaries.
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Figure 1.2: EEG 10–20 Electrode/Channel Placement. The channels correspond to
the number from 1 to 19 starting from the left to right and top to bottom.
Abbreviations: F = frontal, C = central, P = parietal, T = temporal, O =
occipital, Fp = frontopolar. [10]
1.3 Hypoglycaemia-related EEG changes evidence
in the literature
The first studies investigating the relationship between hypoglycaemia and the
EEG signal date back to the 1950 [11]. Since then, several works, e.g.[12] [13] [14],
have proved that a power increase in the low frequency EEG bands takes place
during hypoglycaemia. In [12], Ross and Loeser proved that many patients with
essential hypoglycemia develop disturbances of their cerebral electroactivity during
five hour glucose tolerance tests and that higher blood sugar concentrations are
necessary to prevent cerebral electrical irregularities in younger individuals. In [14],
authors showed that biochemical hypoglycaemia in conscious patients with diabetes
is accompanied by changes in the electroencephalogram: a combined decrease in
alpha activity and increase in theta activity. Eventually, in [13], researchers found
in an unselected group of adolescents with type 1 diabetes EEG abnormalities. In
the frontal regions, the slower frequencies (theta and delta) had an increased power,
in particular the increase in theta activity was most strongly correlated with a
history of severe hypoglycaemia.
These findings stimulated the development of specific algorithms for the prediction
and detection of severe hypoglycaemia events from the analysis of EEG time-
series [16]. In particular, the possibility of using the brain as a biosensor to detect
hypoglycaemia in real-time from suitable processing of EEG signals was largely
investigated within the Hyposafe experience, exhaustively described in [15]. In such
a context, a specific device made of subcutaneous electrodes placed a few millimetres
below the skin and represented in Figure1.4, was used to acquire EEG time-series,
allowing to provide remarkable high quality EEG recordings continuously over long
periods of time [17]. Figure1.3 shows an example of a single channel EEG recorded
during eu- and hypo-glycaemia during daytime, it is evident that the hypoglycaemic
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EEG originates from a process of lower frequency, which is more synchronized,
leading to EEG of higher amplitude [15].
Figure 1.3: Representative examples of single channel EEG recorded during euglycaemia
and hypoglycaemia in the same person [15].
1.4 The Hyposafe device
Figure 1.4: The hyposafe device is implanted under the diabetic’s skin on the side of
the head [17].
The HypoSafe device is the first EEG device made for subcutaneous implantation
[17]. In particular, it is implanted under the diabetic’s skin on the side of the head,
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in the sub cutis layer, only a few millimeters below the skin, making the implant
procedure rather simple. The device can remain implanted for more than 10 years
(depending on regulatory approval). The implanted part is soft and small and
does not create inconvenience to the user. When implanted, there are no physical
elements passing through the skin and the use of bandage/plaster is not required.
Thus, there is no risk of infection or allergic reactions. Furthermore, as the device
is hidden under the skin, it has low implications for the users chosen lifestyle. [17].
The Hyposafe device was developed to real-time process the EEG recordings obtained
through the subcutaneous electrode, in order to individuate when a T1D patient is
approaching the hypoglycaemic condition and to avoid it by providing an alarm.
The Hyposafe team proposed to detect specific changes in the EEG time-series, by
processing the signals through a general mathematical algorithm based on power
estimations and noise indicators, with the aim of detect hypoglycaemia before the
development of cognitive failure [18]. In particular, in [18], hypoglycaemia was
induced in 15 T1D patients not allowed to sleep. EEG was recorded within a
pilot-experiment, to assess if EEG epochs are consistent or not consistent with
hypoglycaemia. Frequency, amplitude and power of the EEG signal recorded were
extracted as features from the pilot experiment to realize the final model. The
final model consists of a curve of integrated events: a window in time domain
weights past hypoglycaemia epochs by integrating events weighted by a kernel. The
threshold value to detect hypoglycaemia is a steep increase above 20 as you can see
in Figure1.5.
Figure 1.5: Integrated events algorithm [18]. You can see the detected events in the
first chart. These events were integrated applying the integration kernel (in
the second chart) and obtaining the integration curve (in the third chart).
You can notice that the integration curve overcames the threshold, thus it’s
generated a warning to the patient.
In [19], the same authors also studied if severe hypoglycaemia is preceded by
changes in both ECG (electrocardiography5) and EEG features by extraction of
5Electrocardiography (ECG or EKG from Greek: kardia, meaning heart) is a transthoracic
(across the thorax or chest) interpretation of the electrical activity of the heart over a period
of time, as detected by electrodes attached to the surface of the skin and recorded by a device
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delta, theta and alpha bands power and QT6 interval features.
Then, they computed ECG and EEG features mean and standard deviation in
a baseline period. If the moving average were greater than the mean plus two
standard deviations, it was detected an hypoglycaemia event (Figure1.6).
Figure 1.6: EEG and ECG features vs plasma glucose measure: you can notice that
EEG theta power increases when the plasma glucose detects hypoglycaemia.
Results, obtained by these works, support the use of the brain as a biosensor
for hypoglycaemia detection.
In [22], it was also tested if hypoglycaemia EEG changes would remain stable
across age, group, gender, duration of diabetes and hypoglycaemia awareness status
in order to establish a very general algorithm for hypoglycaemia detection.
Researchers did a quantitative EEG analysis, based on the the spectral content
of the signal, to find possible group differences among patients classified by age,
gender, duration of diabetes and hypoglycaemia awareness status. They discovered
that their hypoglycaemia indicators were no influenced by these classifications.
Analysis of EEG changes, as a device to detect and predict hypoglycaemia
events, was proposed in some other following papers.
The main results are very similar in all publications:
• the use of subcutaneous electrodes provides a good alternative to surface ones;
• the most sensitive measure of hypoglycemia seems to be a global increase in
theta activity;
external to the body[20].
6In cardiology, the QT interval is a measure of the time between the start of the Q wave
and the end of the T wave in the heart’s electrical cycle. In general, the QT interval represents
electrical depolarization and repolarization of the left and right ventricles.[21]
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• gender and age have no effects.
Researchers also tried to focus their attention on different techniques for
analysing EEG. For instance, they paid attention to the measure of chaos in
the EEG signal in hypoglycaemia in frequency and time domain.
In [23], they utilized a recent index, called reactivity index, to measure its variability
in the standard frequency bands. They found that the reactivity index variability
was higher in hypoglycaemia than in euglycaemia in theta band in Type 1 Diabetes
subjects.
In [24], hypoglycaemia-related EEG changes were investigated by Approximate
Entropy (ApEn) at multiple temporal scales, to assess if EEG complexity changes
during the transition to hypoglycaemia. ApEn is a rather famous entropy measure
introduced by Pincus in 1991 [25] and widely used to study biological time-series,
quantifying the degree of irregularity within a singe time-series: the higher the
ApEn value, the more irregular/complex the signal. The authors showed that
ApEn decreases passing from hyperglycaemia and euglycaemia to hypoglycaemia,
highlighting a decrease of EEG complexity when the hypo condition occurs.
1.5 Aim of the thesis
The aim of this study is to deepen the EEG analysis proposed in the papers
cited in section 1.4 and to investigate if other solid hypoglycaemia indicators can be
defined. In particular, our first specific aim is to reproduce the results of [15]. Then,
we will expand the EEG investigation in more than one channel. Hence, we will
overlap a traditional analysis based on the signal spectral content by personalizing
it, using new indexes and customizing frequency bands.
To facilitate the reading and the following of our line of reasoning, the chapters
are presented in the same order in which they were temporally conceived. In
particular, each chapter is structured as follows: theory behind the method employed,
application to data, results and critical discussion.
The overall results of the thesis will be however summarized in the Conclusions
(Chapter 7).
Chapter 2
Data Base
The data were collected in 19 type-1 diabetic subjects studied at Hillerød
Hospital (Denmark).
An intravenous administration of Actrapid (Novo Nordisk, Bagsværd, Denmark)
was administered to subjects to insulin-induce hypoglycaemia.
EEG and blood glucose concentration (BG) were simultaneously recorded during
the insulin-induced hypoglycaemia experiment.
In particular, BG was frequently determined by a laboratory analyzer YSI (Yellow
Springs In- strument Company, Ohio, USA), while 19 EEG channels were recorded
by standard cap electrodes placed on the scalp according to the 10/20 international
system. EEG was recorded by a digital EEG recorder (Cadwell Easy II, Kennewick,
Washington, USA). EEG signals were analogically low-pass filtered in order to avoid
aliasing, then digitally acquired and finally down-sampled at 64 Hz. The dynamic
range of the EEG was ±4620µV with an amplitude resolution of 0.14 µV . The
internal noise level in the analog data acquisition system was estimated to be 1.3
µV RMS. The protocol was approved by the local ethical committee [24].
Moreover, three 1-hour intervals referred to hyper- eu- and hypoglycaemic conditions
were targeted for each subject thanks to the blood glucose concentration measure.
In Figure2.1, it’s represented the P3-C3 EEG recording and the simultaneous
BG data in a representative subject. The three 1-hour time intervals corresponding
to hyper- eu- and hypo-glycaemia are highlighted by, respectively, red, green and
blue lines. As described in [23], these intervals were determined by visual inspection
of BG time-series. To facilitate the determination of the three intervals and reduce
subjectivity in the analysis, hyper- and hypo-glycaemic thresholds (180 and 70
mg/dl) were compared with a smoothing spline previously fitted against the raw
BG samples by using the method of [26].
The subjects and their time range of observation are summarized in Table2.1.
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Figure 2.1: EEG recording (upper panel) and simulaneous BG measurement. Horizontal
lines in the second panel identify hyperglycaemia (180 mg/dL) and hypogly-
caemia (70 mg/dL) thresholds. Vertical red, green and blue lines refer to
hyper-, eu- and hypo-glycaemia intervals, respectively.
Subject From...To [h] Insulin Shot [h] Hyper [h] Eu [h] Hypo [h]
ERN02 8 a.m-5 p.m. 11.65 a.m. 9-10 a.m 11-12 a.m. 3-4 p.m.
LOH23 9 a.m-1 p.m. 9.91 a.m. 9.17-10.17 a.m 9.67-10.67 a.m. 11.33 a.m.-12.33 p.m.
PET03 9 a.m-5 p.m. 10.31 a.m. 9-10 a.m 11.50-12.50 a.m. 2.50-3.50 p.m.
LAB19 8 a.m-1 p.m. 9.55 a.m. 8.33-9.33 a.m 9.50-10.50 a.m. 11.16 a.m.-12.16 p.m.
SOP11 8 a.m-1 p.m. 10.08 a.m. 8.83-9.83 a.m 10-11 a.m. 11.50 a.m.-12.50 p.m.
ANB20 8 a.m-2 p.m. 8.78 a.m. 8.83-9.83 a.m 9-10 a.m. 11.67 a.m. -12.67 p.m.
CAJ06 8 a.m-2 p.m. 10.75 a.m. 8.67-9.67 a.m 10.17-11.17 a.m. 12.33-1.33 p.m.
GIM27 8 a.m-2 p.m. 10.20 a.m. 8.5-9.5 a.m 9.83-10.83 a.m. 12-1 p.m.
KIP12 8 a.m-2 p.m. 10.47 a.m. 9-10 a.m 10.50-11.50 a.m. 12-1 p.m.
MAA21 8 a.m-2 p.m. 9.75 a.m. 8.83-9.83 a.m 9.67-10.67 a.m. 11.17 a.m.-12.17 p.m.
PEH16 8 a.m-2 p.m. 10.38 a.m. 8.5-9.5 a.m 10-11 a.m. 12-1 p.m.
OLR08 8 a.m-3 p.m. 11.28 a.m. 9-10 a.m 11-12 a.m. 12.67-1.67 p.m.
KIH15 8 a.m-3 p.m. 11.35 a.m. 9-10 a.m 10.67-11.67 a.m. 1.17-2.17 p.m.
ANT09 8 a.m-4 p.m. 11.31 a.m. 8.83-9.83 a.m 10.50-11.50 a.m. 1.50-2.50 p.m.
BOE01 8 a.m-4 p.m. 12.57 a.m. 9.67-10.67 a.m 12-1 p.m. 2-3 p.m.
FLP10 8 a.m-4 p.m. 11.17 a.m. 9-10 a.m 10.50-11.50 a.m. 1-2 p.m.
ETW13 9 a.m-3 p.m. 11.28 a.m. 9.17-10.17 a.m 10.67-11.67 a.m. 1-2 p.m.
PEL26 9 a.m-3 p.m. 11.43 a.m. 9.17-10.17 a.m 11.17 a.m. -12.17 p.m. 1.17-2.17 p.m.
PEN24 9 a.m-3 p.m. 10.67 a.m. 9.17-10.17 a.m 10.50-11.50 a.m. 12.33-1.33 p.m.
Table 2.1: Data base. In the first column the list of subjects, in the second one the total
observation period, in the third one the time of the insulin shot (to induce
hypoglycaemia) and in the remaining columns the three 1-hour intervals
referred to hyper- eu- and hypoglycaemic conditions.
Chapter 3
Spectral density analysis of EEG
and relationships with
hypoglycaemia
The aim of the following study is to clearly show the presence of changes in the
EEG signal through spectral analysis.
A lot of papers, e.g.[18][27], have been written to emphasize these different be-
haviours during hypoglycaemia and euglycaemia.
The main studies are based on the EEG elaboration in the frequency domain. The
EEG signal power or spectral density, in the Fourier domain, was estimated for
every subject for the whole EEG signal. The results were then divided into the
conventional EEG rhytmic activity frequency bands: delta (1-4 Hz), theta (4-8 Hz)
and alpha (8-13 Hz) and into each known period of hypoglycaemia, hyperglycaemia
and euglycaemia.
Our first goal was to reproduce the analysis above and to observe the EEG changes
in each conventional band during the different periods.
The EEG signal was elaborated before the spectral density computation. It was
divided into epochs of few seconds, with or without overlapping with near segments.
In fact, the first problem we faced was how to choose the lenght of the EEG signal
separation, since in the bibliography the choice wasn’t either completely justified or
unanimous:
• 1 second windows without overlapping in [18];
• 4 second windows with a 75% overlapping in [19];
• 4 second windows with a 50% overlapping in [22];
• 4 second windows without overlapping in [13].
For this reason we have chosen to test different durations with different overlap-
pings by processing the signal with the same elaboration and comparing the results.
At the same time, even the choice of the preferable channel used to acquire the
EEG signal isn’t uniform in literature:
• channels P3− T3 and P4− T4 in [19];
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• channels P4− T4 in [22];
• channels F3− C3 (F4− C4) P3−O1 (P4−O2) T3− T5 (T4− T6) in
[28];
• channels C3− A2 A1 in [16]
• channels P3− C3 in [24].
We have decided to cover most of the brain and to test the following bipolar
channel before making a choice:
• F3-C3 (F4-C4);
• P3-C3 (P4-C4);
• P3-T3 (P4-T4).
3.1 Initial division in 2 and 4 second epochs
The first tests have been led by splitting the EEG signal in 2 second epochs
with no overlapping. Then with 4 second epochs with 50% overlapping.
For this initial analysis, we have chosen the P3-C3 channel because it was the most
commonly used in literature.
The signal has been computed with the MATLAB command pwelch, obtaining the
valuation of the power spectral density (PSD) of the input signal, using a Welch
average estimator. Every computed signal segment has been divided in epochs with
a desired lenght and overlapping using an Hamming window 1. This method is
summarized in Figure3.1.
The power spectral density of our signals can display information that is hard
to identify otherwise and it reveals how the power of a signal varies with frequency
[30]. The PSD Gx(f) of a signal xT (t) is defined as:
Gx(f) = limT→∞GxT (f) = limT→∞
|XT (f)|2
T
where
XT (f) =
∫ T/2
−T/2
x(t)e−j2piftdt.
[29]
In Figure3.2, you can see the PSD trend for one of the 19 subjects. The PSD
has a decreasing trend and we can often notice a peak value in the alpha band. It
seems there are not many differences between the two window lengths at first sight,
except for the amplitude of the peak values.
After the PSD computation, we have calculated the mean value of the spectral
density in each traditional frequency band for all subjects in the glycaemic states.
Then, we have statically compared the mean values in each glycaemic state:
1Hamming window is one of the most popular window shapes: w(n) = 0.54− 0.46cos( 2pinN−1 ),
0 ≤ n ≤ N . [29]
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Figure 3.1: The Welch’s method is one technique for signal frequency analysis. The EEG
signal is divided in short time series by applying a window function. Then,
the spectral analysis is applied to each interval, assumed to be stationary
and regular.
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(a) ETW13: 2 second epochs with no overlap
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(b) ETW13: 4 second epochs with 50% overlap
Figure 3.2: P3-C3: PSD
• euglycaemic values vs hypoglycaemic ones.
. We have compared the results performing a t-test (if the data had a standard
normal distribution) or a sign-test (if the data did not verify the t-test assumptions).2
We have plotted our results in Figure3.3 and in Figure3.4. We have summarized
the results of the statistic test in Table3.1 and in Table3.2.
Observing Figure3.3, we can notice that the mean PSD value increases passing
from euglycaemia to hyperglycaemia.
This increase is statically relevant in theta and alpha bands, while the results are
not significant in delta band.
2These statistic tests declare if the means of two groups are statistically different from each
other. The test returns a test decision (0) for the null hypothesis if there are no differences
between means of two groups, it rejects the null hypothesis (1) at the 5% significance level, if the
difference between the population distributions do not have a mean equal to zero.
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2 second length Delta Theta Alpha
Eu vs Hypo 0 1 1
4 second length Delta Theta Alpha
Eu vs Hypo 0 1 1
Table 3.1: Statistic results. 1 stands for statically significant difference, 0 stands for no
significant difference.
2 second length Delta Theta Alpha
Eu vs Hypo 0.6474 7.2 ∗ 10−5 0.0044
4 second length Delta Theta Alpha
Eu vs Hypo 0.6476 5.9 ∗ 10−5 0.0044
Table 3.2: P-values. The p-value indicates the probability that the two population are
not statistically different.
(a) PSD in delta band (b) PSD in theta band (c) PSD in alpha band
Figure 3.3: 2s epoch. Boxplots of PSD mean value in the two glycaemic states from
all subjects. The red line is the median value, the edges of the box are the
75th and 25th percentiles, the red crosses are the outliers. Double stars (**)
indicate statically significant difference, the number near to the double stars
is the p-value.
There are no differences between the 2 second length windowing (Figure3.3) and
the 4 second length windowing (Figure3.4). The results are very similar.
This first study suggests that insulin-induced hypoglycaemia results in an increase
in the power spectral density of the theta and alpha band. Probably, this effect is
due to a reduced brain metabolism, indeed theta and alpha bands indicate relaxing
states. This measure of the PSD seems to be a good tool to detect hypoglycaemic
state.
3.2. CHOICE OF EPOCH LENGTH 15
(a) PSD in delta band (b) PSD in theta band (c) PSD in alpha band
Figure 3.4: 4s epoch. Boxplots of PSD mean value in the two glycaemic states from
all subjects. The red line is the median value, the edges of the box are the
75th and 25th percentiles, the red crosses are the outliers. Double stars (**)
indicate statically significant difference, the number near to the double stars
is the p-value.
3.2 Choice of epoch length
Taking the previous results into account and the window length in the majority
of the papers, we have chosen to use windows of 4 second length. We have decided
to test different overlappings: 0% 50% and 75% for every chosen bipolar channel
(F3-C3, F4-C4; P3-C3, P4-C4; P3-T3, P4-T4).
We have repeated the same frequency analysis of paragraph 3.1:
• computation of the PSD with Welch’s method;
• computation of mean value of the PSD
• statistical analysis and comparison between the euglycaemic state and the
hypoglycaemic one.
In Table3.3 and in Table3.4, we have documented the results from statistics. We
have compared the hypoglyceamic and euglycaemis state in each chosen channel for
all subjects with different overlapping in the EEG windowing. The results about
the channels in the brain left side are in Table3.3, and the ones about the brain
right side are in Table3.4.
We can notice that the channels in the left side are a rich source of information
in alpha and theta band. The worst results in the left side are about F3-C3 channel.
We expected this behaviour because F3-C3 is a frontal channel, so its EEG measure
can be corrupted by the electrooculogram 3.
The channels outcomes of the right side are less informative. The channel F4-
C4 results are surely corrupted by noise, the other channels results highlight a
significant difference only in theta band.
Thus, the most revealing channels seem to be P3-T3 and P3-C3 channels in this
kind of analysis. We can observe P3-T3 PSD mean values in Figure3.5 and P3-C3
PSD mean values in Figure3.6 with the three different overlappings.
3Electro-oculography is a technique for measuring the action potential of the human eye to
record eye-movements.
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Channel % Overlapping Delta (p-value) Theta (p-value) Alpha (p-value)
P3-T3 0% 0 (0.1671) 1 (1.67 ∗ 10−5) 1(0.0192)
50% 0 (0.0631) 1 (3.74 ∗ 10−5) 1(0.0192)
75% 0 (0.0636) 1 (4.89 ∗ 10−5) 1(0.0192)
Channel % Overlapping Delta (p-value) Theta (p-value) Alpha (p-value)
P3-C3 0% 0 (0.6476) 1 (7.56 ∗ 10−5) 1(0.0044)
50% 0 (0.6476) 1 (5.9 ∗ 10−5) 1(0.0044)
75% 0 (0.06476) 1 (1.03 ∗ 10−4) 1(0.0044)
Channel % Overlapping Delta (p-value) Theta (p-value) Alpha (p-value)
F3-C3 0% 0 (0.5464) 0 (0.3435) 1(0.0044)
50% 0 (0.5441) 0 (0.3417) 1(0.0044)
75% 0 (0.5509) 0 (0.3451) 1(0.0044)
Table 3.3: Statistical results for brain left side. In each table, we have reported the
results of the statistics for each channel with three different overlappings. 1
stands for statically significant difference, 0 stands for no significant difference
between euglycaemic and hypoglycaemic state. The p-value (likelihood of no
difference between glycaemic states) is in brakets.
Channel % Overlapping Delta (p-value) Theta (p-value) Alpha (p-value)
P4-T4 0% 0 (0.3593) 1 (0.0044) 0(0.1671)
50% 0 (0.3593) 1 (0.0044) 0(0.1671)
75% 0 (0.3593) 1 (0.0044) 0(0.1671)
Channel % Overlapping Delta (p-value) Theta (p-value) Alpha (p-value)
P4-C4 0% 0 (1) 1 (7.28 ∗ 10−4) 0(0.0636)
50% 0 (1) 1 (7.28 ∗ 10−4) 0(0.0636)
75% 0 (1) 1 (7.28 ∗ 10−4) 0(0.1671)
Channel % Overlapping Delta (p-value) Theta (p-value) Alpha (p-value)
F4-C4 0% 0 (1) 0 (1) 0(0.1671)
50% 0 (1) 0 (1) 0(0.1671)
75% 0 (1) 0 (1) 0(0.1671)
Table 3.4: Statistic results for brain right side. In each table, we have reported the
results of the statistics for each channel with three different overlappings. 1
stands for statically significant difference, 0 stands for no significant difference
between euglycaemic and hypoglycaemic state. The p-value (likelihood of no
difference between glycaemic states) is in brakets.
We have obtained significant results with all three overlappings. Thus, we
have decided to go on using a EEG windowing of 4 second length epochs with
50% overlapping, moreover this percentage is the default choise in the MATLAB
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(a) Theta band: 0% overlapping (b) Theta band: 50% overlapping (c) Theta band: 75% overlapping
(d) Alpha band: 0% overlapping (e) Alpha band: 50% overlapping (f) Alpha band: 75% overlapping
Figure 3.5: P3-T3 channel. Boxplots of PSD mean value in the two glycaemic states
from all subjects. The red line is the median value, the edges of the box are
the 75th and 25th percentiles, the red crosses are the outliers. Double stars
(**) indicate statically significant difference, the number near to the double
stars is the p-value.
methods that we use.
We are satisfied by our outcomes in the brain left side, the value of the PSD
increases passing from euglycaemia to hypoglycaemia and this outcome confirms
the papers results.
The computation of the power spectrum density for the EEG signal can be considered
a standard analysis, because a lot of papers base their dissection on it. So, we have
decided to find different indexes and methods and to test them as hypoglycaemia
indicators.
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(a) Theta band: 0% overlapping (b) Theta band: 50% overlapping (c) Theta band: 75% overlapping
(d) Alpha band: 0% overlapping (e) Alpha band: 50% overlapping (f) Alpha band: 75% overlapping
Figure 3.6: P3-C3 channel. Boxplots of PSD mean value in the two glycaemic states
from all subjects. The red line is the median value, the edges of the box are
the 75th and 25th percentiles, the red crosses are the outliers. Double stars
(**) indicate statically significant difference, the number near to the double
stars is the p-value.
3.3 Other Hypoglycaemia indicators
In addition to the conventional frequency analysis in delta (1 − 4 Hz), theta
(4 − 8 Hz), and alpha (8 − 13 Hz) bands, we have found other useful indexes to
highlight differences among EEG signal in euglycaemia and hypoglycaemia.
The EEG signal of each subject has been divided in epochs of 4 second length,
filtered by a Hamming window with a 50% overlapping as suggested in the paper
[22].
In the publication above, the EEGraphic activity was recorded by subcutaneous
electrodes, placed in P4-T4 position, in awake patients during the daylight.
We chose to reproduce these results and to deepen the analysis by using not only
the P4-T4 position as a source, but also P4-C4, F4-C4 in the right-brain and the
specular bipolar left-brain channels P3-T3, P3-C3, F3-C3.
The studied hypoglycaemia indicators are:
1. peak frequency in the unified theta-alpha (4− 13 Hz) band;
2. centroid in each of the three conventional bands (delta (1−4 Hz), theta (4−8
Hz) e alpha (8− 13 Hz) );
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3. integral of the spectral density and of the logarithm of the squared spectral
density (power spectral density computed with Welch method as in the
previous analysis).
3.3.1 Peak frequency
Observing the subjects’ EEG track in each band, in most cases we have noticed
a peak in the PSD (spectral density) in the unified theta-alpha (4− 13 Hz) band as
you can see in Figure3.2 for the subject ETW13. This peak also seems to change
in magnitude when the patient is in hypoglycaemia.
We have computed the frequency and the amplitude of the peak in the unified
theta-alpha band for each subject in every chosen channel as you can see (for
the left-brain) in Figure3.7 for channel P3-T3, in Figure3.8 for channel P3-C3, in
Figure3.9 for channel F3-C3 and (for the right-brain) in Figure3.10 for channel
P4-T4, in Figure3.11 for channel P4-C4 and in Figure3.12 for channel F4-C4.
We have performed t-test, as usual, to compare the results of all subjects and
to discover significant differences between euglycaemic and hypoglycaemic state.
T-test results are reported in Table3.5
Channel Frequency Amplitude
P3-T3 0 (0.1596) 0 (0.0963)
P3-C3 0 (0.0963) 0 (0.2379)
F3-C3 1 (0.0309) 0 (0.8145)
Channel Frequency Amplitude
P4-T4 1 (0.0309) 1 (0.0309)
P4-C4 0 (0.0963) 0 (0.0963)
F4-C4 0 (0.8145) 0 (0.8145)
Table 3.5: Statistic results for Peak Value. In each table, we have reported the results
of the statistics for each channel for the frequency and amplitude of the peak
value in theta-alpha band. 1 stands for statically significant difference, 0
stands for no significant difference between euglycaemic and hypoglycaemic
state. The p-value (likelihood of no difference between glycaemic states) is in
brakets.
We have noticed that the peak value frequency increases passing from eu-
glycaemia to hypoglycaemia (FigureA.1a, FigureA.2a, FigureA.4a, FigureA.3a,
Figure3.11a, Figure3.12a) while the amplitude behaviour is not uniform in all
channels.
The most significant channel (as you can see in Table3.5) is P4-T4. There’s statically
significant difference between euglycaemia and hypoglycaemia in both frequency
and amplitude of the peak value.
The measure of the peak frequency seems to be a good indicator only in P4-T4
channel.
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Figure 3.7: P3-T3: Peak Value. The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
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Figure 3.8: P3-C3: Peak Value. The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
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Figure 3.9: F3-C3: Peak Value. The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
(a) Frequency (b) Amplitude
Figure 3.10: P4-T4: Peak Value. The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
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Figure 3.11: P4-C4: Peak Value. The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
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Figure 3.12: F4-C4: Peak Value. The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
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3.3.2 Centroid
In the paper [22], the centroid frequency is described as the center of gravity of
each frequency band that subdivides the area under the spectral curve into two of
equal size.
The centroid is also described (for example in [31]) as the spectral baricenter where
the frequencies f(x) are weighted by their likelihood defined as: p(x) = PSD(x)∑N
x=1 PSD(x)
.
centroid_frequency =
∑
(PSD(x)f(x))∑
(PSD(x))
We have chosen to use both definitions to test which one would highlight the most
the differences between eu- and hypoglycaemia. Results are exposed in Figure3.13,
Figure3.14, Figure3.15, Figure3.16, Figure3.17, Figure3.18.
Then, we have performed t-test to compare the results of all subjects and to discover
significant differences between euglycaemic and hypoglycaemic state (results in
Table3.6).
Channel Delta (*) Theta (*) Alpha (*) Delta (**) Theta (**) Alpha (**)
P3-T3 0 (0.1284) 0 (0.2588) 0 (0.1664) 0 (0.1110) 0 (0.2036) 1 (0.0388)
P3-C3 0 (0.1064) 1 (0.0370) 0 (0.2786) 0 (0.1470) 1 (0.0391) 1 (0.0633)
F3-C3 0 (0.0963) 0 (0.0891) 0 (0.2564) 0 (0.3739) 0 (0.0911) 0 (0.3586)
Channel Delta (*) Theta (*) Alpha (*) Delta (**) Theta (**) Alpha (**)
P4-T4 0 (0.8050) 1 (0.0075) 1 (0.0208) 0 (0.4807) 1 (0.0075) 1 (0.0054)
P4-C4 0 (0.8912) 1 (0.0139) 0 (0.1495) 0 (0.7932) 1 (0.0158) 1 (0.0280)
F4-C4 0 (0.2741) 0 (0.0862) 0 (0.5900) 0 (0.3449) 0 (0.1078) 0 (0.8915)
Table 3.6: Statistic results for centroid frequency. In the table, we have reported the
results of the statistics for each channel for the centroid frequency using the
general definition(*) and the paper definition as spectrum median(**). 1
stands for statically significant difference, 0 stands for no significant difference
between euglycaemic and hypoglycaemic state. The p-value (likelihood of no
difference between glycaemic states) is in brakets.
The centroid frequency value seems to decrease in alpha band and to increase
in delta and theta bands as we have summarized in Table3.7.
As you can see in Table3.7, the paper definition (**) is more effective than
the general definition (*) of centroid frequency in discrimination between eu- and
hypo-glycaemia. We can also observe that the centroid frequency could be a hypo-
detector in theta and alpha band because we have obtained statically significant
results in these two bands and a similar behaviour in all channels. Using the
definition of spectrum median (**), the centroid frequency seems to increase in
theta band passing from eu- to hypo-glycaemia and to decrease in alpha band.
Using the general definition (*), we obtain the same result for the centroid frequency
trend.
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Channel Delta (*) Theta (*) Alpha (*) Delta (**) Theta (**) Alpha (**)
P3-T3 ↑ ↑ ↓ ↑ ↑ ↓ •
P3-C3 ↑ ↑ • ↓ ↑ ↑ • ↓ •
P4-T4 ↑ ↑ • ↓ • ↑ ↑ • ↓ •
P4-C4 ↑ ↑ • ↓ ↑ ↑ • ↓ •
F3-C3 ↓ ↑ ↑ ↓ ↑ ↓
F4-C4 ↓ ↑ ↑ ↓ ↑ -
Table 3.7: Centroid frequency trend. We have reported the results for the centroid
frequency using the general definition(*) and the paper definition as spectrum
median(**). Up-arrow (↑) stands for a general increase passing from eu- to
hypo-glycaemia, down-arrow (↓) for a general decrease, bullet (•) for statically
significant difference.
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Figure 3.13: P3-T3: Centroid Frequency. We have reported the results for the centroid
frequency using the general definition(*) and the paper definition as spec-
trum median(***). The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
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Figure 3.14: P3-C3: Centroid Frequency. We have reported the results for the centroid
frequency using the general definition(*) and the paper definition as spec-
trum median(***). The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
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Figure 3.15: F3-C3: Centroid Frequency. We have reported the results for the centroid
frequency using the general definition(*) and the paper definition as spec-
trum median(***). The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
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Figure 3.16: P4-T4: Centroid Frequency. We have reported the results for the centroid
frequency using the general definition(*) and the paper definition as spec-
trum median(***). The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
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Figure 3.17: P4-C4: Centroid Frequency. We have reported the results for the centroid
frequency using the general definition(*) and the paper definition as spec-
trum median(***). The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
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Figure 3.18: F4-C4: Centroid Frequency. We have reported the results for the centroid
frequency using the general definition(*) and the paper definition as spec-
trum median(***). The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
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3.3.3 Power spectrum
We have examined the spectral density trend in the conventional band in the
previous analysis (3.2). We have taken this choice to see if the EEG signal, without
further manipulation, would highlight different behaviors in the selected periods of
euglycemia and hypoglycemia.
In some papers, the EEG signal was further processed studying the integral of the
squared and log transformed PSD, to ensure that the EEG features were normally
distributed [19].
In other publications, it’s studied the integral of the power spectral density to
derive the power of the signal in each bandwith ([fL, fH ]):
Power =
∫ fH
fL
PSD(f)df.
We have repeated a similar frequency analysis of paragraph 3.2:
• computation of the PSD with Welch’s method;
• computation of the PSD integral and of the squared and log transformed PSD
integral;
• computation of mean value of the previous results;
• statistic analysis and comparison between the euglycaemic state and the
hypoglycaemic one.
Eventually, we have chosen to compare the data from the PSD ( and logPSD2)
integral trend with the only PSD trend to see if EEG signal is enough informative
without further manipulation.
The statistics results are presented in Table3.8.
Channel Delta (*) Theta (*) Alpha (*) Delta (**) Theta (**) Alpha (**)
P3-T3 0 (0.0963) 1 (5.05 ∗ 10−5) 1 (0.0309) 1 (0.0219) 1 (5.47 ∗ 10−8) 1 (0.0075)
P3-C3 0 (0.8145) 1 (7.52 ∗ 10−5) 1 (0.0075) 0 (0.4807) 1 (7.10 ∗ 10−5) 1 (0.0024)
F3-C3 0 (0.5170) 0 (0.3328) 1 (0.0075) 0 (1) 0 (0.1047) 1 (8.97 ∗ 10−4)
Channel Delta (*) Theta (*) Alpha (*) Delta (**) Theta (**) Alpha (**)
P4-T4 0 (0.4807) 1 (0.0013) 0 (0.0963) 0 (0.4907) 1 (0.0075) 0 (0.2379)
P4-C4 0 (1) 1 (0.0013) 0 (0.0963) 0 (0.7999) 1 (0.0033) 1 (0.0057)
F4-C4 0 (1) 0 (1) 0 (0.2379) 0 (0.8145) 0 (0.8145) 0 (0.4496)
Table 3.8: Statistic results for PSD and logPSD2 integral. In the table, we have reported
the results of the statistics for each channel for the PSD integral (*) and
the logPSD2 integral (**). 1 stands for statically significant difference, 0
stands for no significant difference between euglycaemic and hypoglycaemic
state. The p-value (likelihood of no difference between glycaemic states) is in
brakets.
We can note that the results in Table3.8 for the two methods of integral
computation are very similar. The logPSD2 integral gains statically difference
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between eu- and hypoglycaemic state in delta band in P3-T3 channel and in alpha
band in P4-C4 channel.
In Table3.9, we have compared the best statistics results of the above analysis
with the results obtained by the testing of the PSD in paragraph 3.2.
Channel Delta (
∫
logPSD2 vs PSD) Theta (
∫
logPSD2 vs PSD) Alpha (
∫
logPSD2 vs PSD)
P3-T3 1 vs 0 1 vs 1 1 vs 1
P3-C3 0 vs 0 1 vs 1 1 vs 1
F3-C3 0 vs 0 0 vs 0 1 vs 0
P4-T4 0 vs 0 1 vs 1 0 vs 0
P4-C4 0 vs 0 1 vs 1 1 vs 0
F4-C4 0 vs 0 0 vs 0 0 vs 0
Table 3.9: PSD: comparison of statistics results. In the table, we have reported the
comparison of the statistics results for each channel for the logPSD2 integral
(**) and for the PSD. 1 stands for statically significant difference, 0 stands
for no significant difference between euglycaemic and hypoglycaemic state.
The logPSD2 integral gains statically difference between eu- and hypoglycaemic
state in alpha band in F3-C3 channel and in P4-C4 channel.
The PSD and the logPSD2 integral (from Figure3.19 to Figure3.24) tendency
is summed up in Table3.10. Their values increases passing from euglycaemia to
hypoglycaemia in all three bands. Thus, the increase in the power spectrum can be
considered another possible indicator of hypoglycaemia, in particular in theta band,
where the statically difference between eu- and hypo-glycaemia is present in most
of the channels (P3-T3, P3-C3, P4-T4, P4-C4). The results in F3-C3 and F4-C4
are not notable as usual.
To sum up, PSD, PSD integral and logPSD2 integral appear to emphasize the
difference between eu- and hypo-glycaemia with similar results. They especially
highlight an increase in the theta power spectrum.
Channel Delta (*) Theta (*) Alpha (*) Delta (**) Theta (**) Alpha (**)
P3-T3 ↑ ↑ • ↑ • ↑ • ↑ • ↑ •
P3-C3 ↑ ↑ • ↑ • ↑ ↑ • ↑ •
P4-T4 ↑ ↑ • ↑ ↑ ↑ • ↑
P4-C4 ↑ ↑ • ↑ ↑ ↑ • ↑ •
F3-C3 - ↑ ↑ • ↑ ↑ ↑ •
F4-C4 ↓ - ↑ ↓ - ↑
Table 3.10: PSD and logPSD2 integral trend. We have reported the results for the
PSD integral (*) and the logPSD2 integral(**). Up-arrow (↑) stands for a
general increase passing from eu- to hypo-glycaemia, down-arrow (↓) for a
general decrease, bullet (•) for statically significant difference.
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Figure 3.19: P3-T3: PSD and logPSD2 integral. We have reported the results for
the PSD integral (*) and the logPSD2 integral(***). The red line is the
median value, the edges of the box are the 75th and 25th percentiles, the
red crosses are the outliers. Double stars (**) indicate statically significant
difference, the number near to the double stars is the p-value.
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Figure 3.20: P3-C3: PSD and logPSD2 integral. We have reported the results for
the PSD integral (*) and the logPSD2 integral(***). The red line is the
median value, the edges of the box are the 75th and 25th percentiles, the
red crosses are the outliers. Double stars (**) indicate statically significant
difference, the number near to the double stars is the p-value.
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Figure 3.21: F3-C3: PSD and logPSD2 integral. We have reported the results for
the PSD integral (*) and the logPSD2 integral(***). The red line is the
median value, the edges of the box are the 75th and 25th percentiles, the
red crosses are the outliers. Double stars (**) indicate statically significant
difference, the number near to the double stars is the p-value.
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Figure 3.22: P4-T4: PSD and logPSD2 integral. We have reported the results for
the PSD integral (*) and the logPSD2 integral(***). The red line is the
median value, the edges of the box are the 75th and 25th percentiles, the
red crosses are the outliers. Double stars (**) indicate statically significant
difference, the number near to the double stars is the p-value.
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Figure 3.23: P4-C4: PSD and logPSD2 integral. We have reported the results for
the PSD integral (*) and the logPSD2 integral(***). The red line is the
median value, the edges of the box are the 75th and 25th percentiles, the
red crosses are the outliers. Double stars (**) indicate statically significant
difference, the number near to the double stars is the p-value.
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Figure 3.24: F4-C4: PSD and logPSD2 integral. We have reported the results for
the PSD integral (*) and the logPSD2 integral(***). The red line is the
median value, the edges of the box are the 75th and 25th percentiles, the
red crosses are the outliers. Double stars (**) indicate statically significant
difference, the number near to the double stars is the p-value.
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3.4 Possible margins of improvement
Observing the whole results, the F3-C3 and F4-C4 channels do not show
significant outcomes. Taking their brain position in consideration, these channels
would probably interfere with the EOG, so these signals need a pre-elaboration to
be used in the hypoglycaemia detection.
We have decided to discard the use of F3-C3 and F4-C4 channels to avoid a
pre-elaboration of the signal and because of the informative results that can be
estimated by the other channels.
Our frequency analysis is founded on the comparison between euglycaemia and
hypoglycaemia, so it would be of interest to involve the 15/30 minute period before
the hypoglycaemic one to try to give a warning to the patient.
Moreover, it would be interesting to see if the EEG signal is also informative in the
time domain.
Eventually, the frequency analysis could be improved by computing subjective
boundaries for the three frequency bands (delta, theta and alpha) for each patient
and by basing the study on utilizing these new bands.
So, in Chapter 4, we have decided to focus on personalizing the alpha band,
because of the significant results obtained in this EEG frequency range, and then on
computing again all the hypoglycaemic indicators in the new alpha band limitations.
Chapter 4
Spectral analysis with EEG alpha
band individualization
We used the conventional bands (delta (1−4 Hz), theta (4−8 Hz) e alpha (8−13
Hz)) to compute the spectral density and the other hypoglycaemia indicators.
We wondered if the limitations of these bands could be customized for each subject
and if the same indicators, in the personalized bands, could improve by being more
effective.
In the paper [32], it’s discussed the well-known approaches to compute the individual
alpha frequency (the peak frequency in the alpha band).
The first step to investigate the alpha frequency is to detect the personalized alpha
band for each subject.
We have decided to exploit this approach to detect the personalized alpha band for
each subject and to compute again all the hypoglycaemic indicators with these new
limitations.
We present this simple pilot-study to evaluate if it’s worth undertaking this task.
4.1 The extended band (EB) method
The extended band (EB) method was proposed by Klimesh et al. in the 1990
[33]. It’s based on visual inspecting, thus it results subjective, and it’s applied to
a resting spectrum. In our study, we have chosen the PSD during euglycemia as
resting spectrum.
EB method consists of a few steps:
1. EEG spectra without detectable alpha peak are discarded by visually inspect-
ing;
2. the starting point of the ascending edge is considered as f1 by visually
inspecting;
3. the ending point of the descendind edge is considered as f2 by visually
inspecting;
4. the extended alpha band (from f1 to f2) is detected by averaging the bound-
aries obtained by each channel.
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The first step is to discard EEG resting spectra without a detecable alpha peak.
We found three subjects to be discarded in our database: PET03, KIP12 and
OLR08 (in Figure4.1).
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(c) OLR08
Figure 4.1: EB method: PSD discarded
Then, we have computed the boundaries for each subject, obtaining the values
in Figure4.2.
Figure 4.2: EB method: application to all subjects
For instance, in Figure4.3, we have reported the resting spectrum (euglycaemic
PSD) in each channel and the boundaries (red vertical lines) computed for subject
ETW13.
4.2 Implementation
We have calculated the same hypoglycaemia indicators in the personalized alpha
band to compare them with the results in the conventional band.
We have computed the centroid frequency and the integral of both the spectral
density and the logarithm of the squared spectral density in the new alpha band
for each of the following channel:
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Figure 4.3: EB method: subject ETW13. We can see euglycaemic PSD in all selected
channels in different colours. The vertical red lines stand for the boundaries
of the personalized alpha band.
• P3-T3 (P4-T4)
• P3-C3 (P4-C4).
We have omitted the channels F3-C3 and F4-C4 from this analysis, because they
did not display good results in the above paragraphs.
We show the results divided for each channel from Figure4.4 to Figure4.7.
4.3 Results
We have performed the usual statistical comparison between eu- and hypo-
glycaemia results to emphasize the significant difference. The results are summed
up in Table4.1.
The outcomes are very satisfactory, in particular if we compare them with the
ones obtained by the previous analysis, (as you can see in Table4.2).
We have earned statically difference in the centroid frequency for channels
P3-T3, P3-C3 and P4-C4, and in the power spectrum for channel P4-T4, thanks to
the alpha band personalization.
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Channel Centroid frequency (*) Centroid frequency (**)
∫
PSD
∫
logPSD2
P3-T3 1 (0.0011) 1(8.44 ∗ 10−5) 1 (0.0059) 1 (0.0023)
P3-C3 1 (3.5 ∗ 10−4) 1(1.65 ∗ 10−4) 1 (0.0245) 1 (0.0075)
P4-T4 1 (0.0370) 1(0.0213) 1 (0.0213) 0 (0.0914)
P4-C4 1 (9.95 ∗ 10−5) 1(5.79 ∗ 10−5) 0 (0.1013) 1 (0.0073)
Table 4.1: Statistic results for the alpha band personalization. We have reported the
results of the statistics for each channel. 1 stands for statically significant
difference, 0 stands for no significant difference between euglycaemic and
hypoglycaemic state. The p-value (likelihood of no difference between gly-
caemic states) is in brakets. (*) stands for the centroid frequency computed as∑
(PSD(x)f(x))∑
(PSD(x)) , (**) stands for the centroid frequency computed as spectrum
median.
Channel Centroid frequency (*) Centroid frequency (**)
∫
PSD
∫
logPSD2
P3-T3 1 (0) 1(1) 1 (1) 1 (1)
P3-C3 1 (0) 1(0) 1 (1) 1 (1)
P4-T4 1 (1) 1(1) 1 (0) 0 (0)
P4-C4 1 (0) 1(1) 0 (1) 1 (1)
Table 4.2: Comparison between the analysis based on the alpha band personalized
and the conventional analysis based on the standard alpha band (results
in brakets). 1 stands for statically significant difference, 0 stands for no
significant difference between euglycaemic and hypoglycaemic state. (*)
stands for the centroid frequency computed as
∑
(PSD(x)f(x))∑
(PSD(x)) , (**) stands for
the centroid frequency computed as spectrum median.
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(a) Centroid frequency (*) (b) Centroid frequency (***)
(c)
∫
PSD (d)
∫
logPSD2
Figure 4.4: P3-T3: alpha band personalization. (*) stands for the centroid frequency
computed as
∑
(PSD(x)f(x))∑
(PSD(x)) , (***) stands for the centroid frequency computed
as spectrum median. The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
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(a) Centroid frequency (*) (b) Centroid frequency (***)
(c)
∫
PSD (d)
∫
logPSD2
Figure 4.5: P3-C3: alpha band personalization. (*) stands for the centroid frequency
computed as
∑
(PSD(x)f(x))∑
(PSD(x)) , (***) stands for the centroid frequency computed
as spectrum median. The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
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(a) Centroid frequency (*) (b) Centroid frequency (***)
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∫
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Figure 4.6: P4-T4: alpha band personalization. (*) stands for the centroid frequency
computed as
∑
(PSD(x)f(x))∑
(PSD(x)) , (***) stands for the centroid frequency computed
as spectrum median. The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
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(a) Centroid frequency (*) (b) Centroid frequency (**)
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Figure 4.7: P4-C4: alpha band personalization. (*) stands for the centroid frequency
computed as
∑
(PSD(x)f(x))∑
(PSD(x)) , (***) stands for the centroid frequency computed
as spectrum median. The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
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4.4 Possible margins of improvement
This pilot-study has stressed that the band personalization can improve the
results. It suggests that it could be useful pre-processing the EEG signal to
compute the personalized bands. The research of the subjective boundaries could
be considered as a device-calibration in the system to detect hypoglycaemia.
Unfortunately, the method used to customize the alpha band is a subjective method,
so this analysis could be further enhanced for instance, by the Channel Reactivity
Based (CRB) method recently presented in [32].

Chapter 5
Use of a new reactivity index
measure to detect hypoglycaemia
5.1 The reactivity index
This chapter is based on the idea of the paper [23], which investigated if and how
levels of glucose concentrations affect the time course of EEG power modulations
in the conventional theta, alpha and beta bands. This was done by studying the
variability of the EEG signal exploiting the reactivity index ρ.
The reactivity index was introduced in the paper [32]. It quantifies the EEG power
decrease between a reference and a test interval.
Briefly, we choose a reference r(t) and a test t(t) interval from a time series. Then,
we compute the power spectrum of the test T (f) and the reference R(f) interval in
the chosen frequency band [fa, fb]. Now, we can calculate the reactivity index as:
ρ =
∫ fb
fa
R(f)− T (f)
fb − fa [
µV 2
Hz
].
∫ fb
fa
R(f) − T (f) represents the area delimited by the resting and test spectra in
the frequency interval [fa, fb]. So, a positive value of ρ stands for a power decrease
and a negative value for a power increase.
5.2 Implementation
We have decided to follow the procedure of the paper [23] for dealing with the
EEG variability computation.
It consists of a few passages:
• selection of EEG signal in time domain;
• selection of a series of couples: reference and test time intervals (ri(t), ti(t))
(they last 2 minutes and they distance 10 minutes. The successive couple
(r2(t), t2(t)) is obtained by shifting r1(t) and t2(t) by 0.5 minutes);
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• computation of the power spectral density of each couple ((ri(t), ti(t)) →
(Ri(f), Ti(f)));
• computation of the reactivity index for each couple ρi =
∫ fb
fa
Ri(f)−Ti(f)
fb−fa .
• selection of ρ belonging to 1 hour EEG time interval;
These steps were repeated for each subject and for the alpha, theta and beta bands.
For each patient, the 1 hour EEG time intervals were selected from the hypogly-
caemia and then from the euglycaemia period.
The PSD of the couple (ri(t), ti(t)) is obtained by applying the Welch method in
EEG 2 second length epoch with no overlapping.
Moreover, the EEG signal was pre-elaborated for this analysis, thus we have ex-
cluded EEG values with amplitude greater than 100, because they were surely
artifacts.
The above steps are summarized in Figure5.1.
Figure 5.1: Reactivity Index computation.
At the end of this elaboration, we have obtained 30 ρ values for the hypogly-
caemic period and 30 ρ values for the euglycaemic period. Then, we have computed
their standard deviation and performed a statistic test with all the results from all
subjects.
5.3 Results
We have reported our statistic outcomes in Table 5.1 on the facing page.
As you can see in Table5.1, the EEG variability is significant in theta band, where
the EEG variability seems to increase passing from euglycaemia to hypoglycaemia,
as you can notice from Figure5.2 to Figure5.5.
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Channel Alpha Theta Beta
P3-T3 0 (0.8978) 1 (0.0044) 0 (0.9570)
P3-C3 0 (0.1671) 1 (4.29 ∗ 10−4) 0 (0.0636)
P4-T4 0 (0.3595) 1 (0.0096) 0 (0.2771)
P4-C4 0 (0.3593) 1 (0.0014) 0 (0.3593)
Table 5.1: Statistic results for ρ computation. We have reported the results of the
statistics for each channel. 1 stands for statically significant difference, 0
stands for no significant difference between euglycaemic and hypoglycaemic
state. The p-value (likelihood of no difference between glycaemic states) is in
brakets.
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Figure 5.2: P3-T3: standard deviation of reactivity index. The red line is the median
value, the edges of the box are the 75th and 25th percentiles, the red crosses
are the outliers. Double stars (**) indicate statically significant difference,
the number near to the double stars is the p-value.
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Figure 5.3: P3-C3: standard deviation of reactivity index. The red line is the median
value, the edges of the box are the 75th and 25th percentiles, the red crosses
are the outliers. Double stars (**) indicate statically significant difference,
the number near to the double stars is the p-value.
The overall results are satisfying. The reactivity index highlight that its ap-
plication in theta band can be a good indicator for hypoglycaemia detection. In
Table5.2, we have reported, from statistics, the median and the 75th and the 25th
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Figure 5.4: P4-T4: standard deviation of reactivity index. The red line is the median
value, the edges of the box are the 75th and 25th percentiles, the red crosses
are the outliers. Double stars (**) indicate statically significant difference,
the number near to the double stars is the p-value.
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Figure 5.5: P4-C4: standard deviation of reactivity index. The red line is the median
value, the edges of the box are the 75th and 25th percentiles, the red crosses
are the outliers. Double stars (**) indicate statically significant difference,
the number near to the double stars is the p-value.
percentile of the values in theta band for each channel to highlight the comparison
between eu- and -hypoglycaemia and to confirm the increase in variability.
5.4 Possible margins of improvement
This measurement of the reactivity index variability has led to good results.
Probably, they can be refined with a different choice of reference and test intervals.
We have decided to use reference/test intervals of 2 minute length and a 0.5 minutes
distance from each other. Moreover, the distance between the reference interval
and its test was of 10 minutes. Maybe, we can improve the outcomes changing the
value of these three parameters and comparing the results.
Furthermore, the reactivity index variability could be an adequate instrument to
test the difference between euglycaemic and pre-hypoglycaemic period (circa 30
minutes before).
The reactivity index study could be amplified and improved in this way.
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P3-T3: Eu Hypo P3-C3: Eu Hypo
median 0.8923 1.5242 0.47689 1.1314
75th percentile 1.9841 2.963 1.026 2.0228
25th percentile 0.54673 0.88784 0.41861 0.60675
P4-T4: Eu Hypo P4-C4: Eu Hypo
median 1.2158 1.571 0.54828 1.207
75th percentile 1.9947 3.238 1.0638 2.297
25th percentile 0.60016 0.78108 0.44324 0.52156
Table 5.2: Reactivity index variability passing from euglycaemia to hypoglycaemia. The
25th percentile, the median value and the 75th percentile are presented to
emphasize the increase in variability in hypoglycaemia.

Chapter 6
Conclusions and future challanges
6.1 Summary of the overall results
People with type 1 diabetes require insulin therapy and other treaments to live
long and healthy. In particular, they need to avoid hypoglycaemic events. The
use of the brain as biosensor has been recently proposed along with the Hyposafe
device in order to further investigate its potential to detect hypoglycaemia and to
try to improve patients condition.
In the present thesis, we have studied some refinements as well as some new tech-
niques to process the EEG to detect hypoglycaemia.
We have managed data from 19 subjects exposed to insulin-induced hypoglycaemia.
We have tested and applied different methods to the following bipolar channel:
F3-C3, F4-C4, P3-C3, P4-C4, P3-T3, P4-T4 (we have soon left out F3-C3 and
F4-C4 channels from our analysis because they do not show significant outcome
since they probably interfere with the EOG).
The outcomes of the initial analysis (the spectral measures in the conventional
bands) reveal an increase in the power spectral density (PSD) in theta and alpha
band. In particular, the left brain channels (P3-T3, P3-C3) show a statistical
notable increase in both theta and alpha band passing from euglycaemia to hypogly-
caemia, while the right brain channels (P4-T4, P4-C4) exhibit a significant increase
only in theta band. We can deduce that the left brain seems to be a preferable
brain side to apply this kind of analysis.
Observing the subjects’ PSD track in each band, in most cases we have noticed a
peak in the unified theta-alpha (4-13 Hz) band, but only the P4-T4 channel shows
a statistically significant difference in both magnitude and frequency of this peak
passing from eu- to hypo-glycaemia.
About the centroid frequency, P3-C3, P3-T3 and P4-T4 channels reveal a statistical
significant increase in theta band and a significant statistical decrease in alpha
band, passing from euglycaemia to hypoglycaemia, using the paper [22] definition,
while only P4-T4 shows a significant statistical outcome in both bands as spectral
baricenter.
Computing the integral of the squared and log transformed PSD we have found
best results in the left brain . To be specific, we have noted an increase in theta and
alpha band passing from euglycaemia to hypoglycaemia. The results were statically
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significant in P3-T3, P3-C3 and P4-C4 channels in both alpha and theta bands.
But, we were interested in comparing the data from the PSD (and logPSD2) inte-
gral trend with the PSD trend to see if EEG signal without further manipulation
was enough informative. We have noticed that we have gained statistical difference
only in alpha band in P4-C4 channel using the logPSD2 integral.
Thus, if we were interested only in analysing the EEG changes in theta band, we
could simply exploit the PSD trend.
Exploiting the personalized alpha band for each subject to compute again all the
hypoglycaemic indicators with these new limitations, we have obtained outstand-
ing outcomes. We have earned in statistical difference between euglycaemia and
hypoglycaemia in both centroid frequency definitions in P3-T3, P3-C3 and P4-C4
channels. We have also gained statistical difference in P4-T4 channel in PSD
integral and in squared and log transformed PSD integral.
We have once again obtained best results in the left side of the brain.
Eventually, we have tested that the EEG variability changes passing from eu-
glycaemia to hypoglycaemia exploiting the reactivity index. We have reached
important results in theta band in all channels (P3-T3, P3-C3, P4-T4, P4-C4): ρ
variability increases passing from euglycaemia to hypoglycaemia.
To sum up, the increase in PSD value in theta band, the increase in the cen-
troid frequency and the reactivity index variability have demonstrated that there
are remarkable EEG changes passing from euglycaemia to hypoglycaemia. These
parameters could be integrated with the hyposafe device to detect hypoglycaemic
events, but these techniques can and still need to be improved.
6.2 Possible further developments
For istance, we have proved that the use of subjective boundaries for the alpha
band has enhanced the results. So, it could be useful to compute personalized limits
for both alpha and theta band, utilizing this passage as a device calibration before
its daily use. But, we need to use a more powerful and more objective method
to personalize the frequency band such as the Channel Reactivity Based Method
proposed in [32].
Maybe, the reactivity index variability could be more perceptive using personalized
frequency bands and changing its basic parameters.
Moreover, we should try to apply all the presented methods in the 15-30 minute
period before the hypoglycaemic state to give a warning to the patient. Thus,
we demand a detailed analysis comparing the pre-hypoglycaemic state with the
euglycaemic one in order to discover if these techniques continue to be robust in
the glycaemic states comparison.
In the end, this study was mainly based on the frequency domain, it would be inter-
sting to deepen the time domain analysis to research hypoglycaemic peculiarities.
Appendix A
Hyperglycaemia vs hypoglycaemia
The main goal of this study was to show the presence of changes in the EEG
signal passing from euglycaemia to hypoglycaemia.
The above analysis has also been led comparing:
• hyperglycaemia to euglycaemia;
• hyperglycaemia to hypoglycaemia.
In this appendix, we present a brief excursus of all previous methods, highlighting
the comparison between hyperglycaemia to euglycaemia and hyperglycaemia to
hypoglycaemia.
We have decided to propose directly the analysis in the following channels:
• P3-C3 (P4-C4);
• P3-T3 (P4-T4).
A.1 Hypoglycaemia indicators
The EEG signal of each subject has been divided in epochs of 4 second length,
filtered by a Hamming window with a 50% overlapping.
Then, we have studied:
1. peak frequency in the unified theta-alpha (4-13 Hz) band;
2. centroid in each of the three conventional bands (delta (1-4 Hz), theta (4-8
Hz) e alpha (8-13 Hz) );
3. integral of the spectral density and of the logarithm of the squared spectral
density.
A.1.1 Peak frequency
We have computed the frequency and the amplitude of the peak in the unified
theta-alpha band for each subject in every chosen channel. We have performed
t-test, as usual, to compare the results of all subjects and to discover significant
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Channel Glycaemic states difference Frequency Amplitude
P3-T3 hyper-eu 0 (0.1893) 1 (0.0309)
P3-T3 hyper-hypo 0 (0.0427) 1 (0.0013)
P3-C3 hyper-eu 0 (0.4807) 1 (0.0013)
P3-C3 hyper-hypo 0 (0.4807) 1 (0.0189)
Channel Glycaemic states difference Frequency Amplitude
P4-T4 hyper-eu 0 (0.1893) 1 (0.0075)
P4-T4 hyper-hypo 1 (0.0427) 1 (0.0013)
P4-C4 hyper-eu 0 (0.2379) 1 (0.0075)
P4-C4 hyper-hypo 0 (0.4807) 1 (1.45 ∗ 10−4))
Table A.1: Statistic results for Peak Value. In each table, we have reported the results
of the statistics for each channel for the frequency and amplitude of the peak
value in theta-alpha band. 1 stands for statically significant difference, 0
stands for no significant difference between euglycaemic and hypoglycaemic
state. The p-value (likelihood of no difference between glycaemic states) is
in brakets.
differences between hyperglycaemic and hypoglycaemic state and hyperglycaemic
and euglycaemic state. The results are in TableA.1.
As you can notice in TableA.1, the amplitude of the peak changes its value
passing from hyperglycaemia to hypo- or eu-glycaemia.
As you can see from FigureA.1 to FigureA.4 , it seems to increases passing from
hyperglycaemia to euglycaemia and from euglycaemia to hypoglycaemia.
(a) Frequency (b) Amplitude
Figure A.1: P3-T3: Peak Value. The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
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(a) Frequency (b) Amplitude
Figure A.2: P3-C3: Peak Value. The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
(a) Frequency (b) Amplitude
Figure A.3: P4-T4: Peak Value. The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
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(a) Frequency (b) Amplitude
Figure A.4: P4-C4: Peak Value. The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
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A.1.2 Centroid
The centroid frequency has been described:
• as the spectral baricenter where the frequencies f(x) are weighted by their
likelihood PSD(x);
• as "the center of gravity of each frequency band that subdivides the area
under the spectral curve into two of equal size".
We have chosen to use both definitions to test which one would highlight the
most the differences between the different glycaemic states.
Then, we have performed t-test to compare the results of all subjects (TableA.2).
Channel Glycaemic states difference Delta (*) Theta (*) Alpha (*) Delta (**) Theta (**) Alpha (**)
P3-T3 hyper-eu 0 (0.4505) 0 (0.5247) 1 (0.0075) 0 (0.5011) 0 (0.0963) 1 (0.0075)
P3-T3 hyper-hypo 1 (0.0411) 0 (0.2649) 1 (0.0011) 0 (0.0658) 1 (0.0075) 1 (0.0309)
P3-C3 hyper-eu 0 (1) 0 (0.0185) 1 (0.2379) 0 (0.8145) 0 (0.1435) 1 (0.0055)
P3-C3 hyper-hypo 0 (0.3635) 0 (0.0089) 1 (0.0132) 0 (0.4089) 1 (0.0390) 1 (0.0185)
Channel Glycaemic states difference Delta (*) Theta (*) Alpha (*) Delta (**) Theta (**) Alpha (**)
P4-T4 hyper-eu 0 (0.7710) 0 (0.4807) 0 (0.1959) 0 (0.8145) 1 (0.0075) 1 (0.0015)
P4-T4 hyper-hypo 0 (0.9369) 0 (0.0748) 1 (7.56 ∗ 10−4) 0 (0.8615) 1 (0.0093) 1 (0.0182)
P4-C4 hyper-eu 0 (0.2379) 1 (0.0309) 0 (0.8145) 1 (0.0272) 0 (0.0963) 1 (0.0021)
P4-C4 hyper-hypo 0 (0.1350) 1 (0.0041) 1 (0.0105) 0 (0.1069) 0 (0.0932) 0 (0.0963)
Table A.2: Statistic results for centroid frequency. In the table, we have reported the
results of the statistics for each channel for the centroid frequency using the
general definition(*) and the paper definition as spectrum median(**). 1
stands for statically significant difference, 0 stands for no significant difference
between euglycaemic and hypoglycaemic state. The p-value (likelihood of no
difference between glycaemic states) is in brakets.
You can see the trend of the centroid in delta, theta and alpha band from
FigureA.5 to FigureA.8 in all channels. It seems to decrease in alpha band using
the centroid definition and it seems to increase in theta band using both definitions.
The statistic results (TableA.2) suggest us that the more relevant outcomes are in
alpha and theta band with the paper definition (centroid computed as spectrum
median).
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Figure A.5: P3-T3: Centroid Frequency. We have reported the results for the centroid
frequency using the general definition(*) and the paper definition as spec-
trum median (***). The red line is the median value, the edges of the box
are the 75th and 25th percentiles, the red crosses are the outliers. Double
stars (**) indicate statically significant difference, the number near to the
double stars is the p-value.
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Figure A.6: P3-C3: Centroid Frequency. We have reported the results for the centroid
frequency using the general definition (*) and the paper definition as
spectrum median(***). The red line is the median value, the edges of
the box are the 75th and 25th percentiles, the red crosses are the outliers.
Double stars (**) indicate statically significant difference, the number near
to the double stars is the p-value.
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Figure A.7: P4-T4: Centroid Frequency. We have reported the results for the centroid
frequency using the general definition (*) and the paper definition as
spectrum median(***). The red line is the median value, the edges of
the box are the 75th and 25th percentiles, the red crosses are the outliers.
Double stars (**) indicate statically significant difference, the number near
to the double stars is the p-value.
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Figure A.8: P4-C4: Centroid Frequency. We have reported the results for the centroid
frequency using the general definition (*) and the paper definition as
spectrum median (***). The red line is the median value, the edges of
the box are the 75th and 25th percentiles, the red crosses are the outliers.
Double stars (**) indicate statically significant difference, the number near
to the double stars is the p-value.
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A.1.3 Power spectrum
We have also studied the integral of the power spectral density to derive the
power of the signal in each bandwith ([fL, fH ]).
In short, we have:
• computed the PSD with Welch’s method;
• computed the PSD integral and of the squared and log transformed PSD
integral;
• computed the mean value of the previous results;
• made the statistic analysis and compared hyperglycaemic state and hypogly-
caemic one.
We report the results for the four channels (TableA.3, from FigureA.9 to
FigureA.12).
Channel Glycaemic states difference Delta (*) Theta (*) Alpha (*) Delta (**) Theta (**) Alpha (**)
P3-T3 hyper-eu 0 (0.4307) 0 (0.0963) 1 (0.0075) 0 (0.4807) 1 (0.0309) 1 (0.0079)
P3-T3 hyper-hypo 1 (0.0309) 1 (1.45 ∗ 10−4) 0 (0.0963) 1 (0.0075) 1 (1.45 ∗ 10−4) 1 (0.0012)
P3-C3 hyper-eu 0 (0.4807) 1 (0.0357) 1 (0.0013) 0 (0.4807) 1 (0.0309) 1 (1.45 ∗ 10−4)
P3-C3 hyper-hypo 1 (0.0100) 1 (7.26 ∗ 10−6) 1 (0.0075) 0 (0.0963) 1 (7.62 ∗ 10−6) 1 (2.18 ∗ 10−4)
Channel Glycaemic states difference Delta (*) Theta (*) Alpha (*) Delta (**) Theta (**) Alpha (**)
P4-T4 hyper-eu 1 (0.0309) 1 (0.0075) 1 (0.0013) 1 (0.0309) 1 (0.0013) 1 (0.0013)
P4-T4 hyper-hypo 1 (0.0013) 1 (1.45 ∗ 10−4) 1 (0.0013) 1 (0.0013) 1 (1.45 ∗ 10−4) 1 (0.0017)
P4-C4 hyper-eu 0 (0.0963) 0 (0.0963) 1 (0.0075) 0 (0.2379) 0 (0.0963) 1 (1.45 ∗ 10−4)
P4-C4 hyper-hypo 1 (0.0127) 1 (1.45 ∗ 10−4) 1 (0.0013) 0 (0.0963) 1 (1.45 ∗ 10−4) 1 (6.35 ∗ 10−4)
Table A.3: Statistic results for PSD and logPSD2 integral. In the table, we have
reported the results of the statistics for each channel for the PSD integral (*)
and the logPSD2 integral (**). 1 stands for statically significant difference,
0 stands for no significant difference between euglycaemic and hypoglycaemic
state. The p-value (likelihood of no difference between glycaemic states) is
in brakets.
We can notice a general increase in the power spectrum in all subjects passing
from hyper- to eu-glycaemia and from eu- to hypo-glycaemia.
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(d) Alpha band (***) (e) Alpha band (***) (f) Alpha band (***)
Figure A.9: P3-T3: PSD integral (*) and logPSD2 integral (***). We have reported
the results for the PSD integral and the logPSD2 integral. The red line is
the median value, the edges of the box are the 75th and 25th percentiles, the
red crosses are the outliers. Double stars (**) indicate statically significant
difference, the number near to the double stars is the p-value.
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Figure A.10: P3-C3: PSD integral (*) and logPSD2 integral(***). We have reported
the results for the PSD integral and the logPSD2 integral. The red line is
the median value, the edges of the box are the 75th and 25th percentiles,
the red crosses are the outliers. Double stars (**) indicate statically
significant difference, the number near to the double stars is the p-value.
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(a) Theta band (*) (b) Theta band (*) (c) Theta band (*)
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Figure A.11: P4-T4: PSD integral (*) and logPSD2 integral (***). We have reported
the results for the PSD integral and the logPSD2 integral. The red line is
the median value, the edges of the box are the 75th and 25th percentiles,
the red crosses are the outliers. Double stars (**) indicate statically
significant difference, the number near to the double stars is the p-value.
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Figure A.12: P4-C4: PSD integral (*) and logPSD2 integral (***). We have reported
the results for the PSD integral and the logPSD2 integral. The red line is
the median value, the edges of the box are the 75th and 25th percentiles,
the red crosses are the outliers. Double stars (**) indicate statically
significant difference, the number near to the double stars is the p-value.
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A.2 EB method
We have computed the personalized alpha band for each subject with the EB
method.
Next, we have calculated the same hypoglycaemia indicators in the personalized
alpha band to compare them with the results in the conventional band.
Channel Glycaemic states difference Centroid frequency (*) Centroid frequency (**)
∫
PSD
∫
logPSD2
P3-T3 hyper-eu 0 (0) 0 (1) 1 (1) 1 (1)
P3-T3 hyper-hypo 1 (1) 1 (1) 1 (0) 1 (1)
P3-C3 hyper-eu 0 (0) 0 (1) 1 (1) 1 (1)
P3-C3 hyper-hypo 1 (1) 0 (1) 1 (1) 1 (1)
P4-T4 hyper-eu 0 (0) 0 (1) 1 (1) 1 (1)
P4-T4 hyper-hypo 1 (1) 1 (1) 1 (1) 1 (1)
P4-C4 hyper-eu 0 (0) 0 (1) 1 (1) 1 (1)
P4-C4 hyper-hypo 0 (1) 0 (0) 1 (1) 1 (1)
Table A.4: Statistic results for the alpha band personalization. We have reported the
results of the statistics for each channel. 1 stands for statically significant
difference, 0 stands for no significant difference between euglycaemic and
hypoglycaemic state. The statistic result with the conventional band is in
brakets. (*) stands for the centroid frequency computed as
∑
(PSD(x)f(x))∑
(PSD(x)) ,
(**) stands for the centroid frequency computed as spectrum median.
Observing the outcomes in TableA.4, the results are not good for the centroid
frequency. We have lost in statistical significance in all channels in the hyper-
and eu-glycaemia comparison, computing the centroid frequency as
∑
(PSD(x)f(x))∑
(PSD(x))
.
We have also lost in statistical significance in P4-C4 channel in hyper- and hypo-
glycaemia comparison.
There are no difference for the
∫
logPSD2.
We have gained in statistical significance in P3-T3 channel in hyper- and hypo-
glycaemia comparison for the PSD integral.
To sum up, the alpha band personalization appears to be not necessary in the
comparison between hyperglycaemia and eu/hypoglycaemia.
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(a) Centroid frequency (*) (b) Centroid frequency (***)
(c)
∫
PSD (d)
∫
logPSD2
Figure A.13: P3-T3: alpha band personalization. (*) stands for the centroid frequency
computed as
∑
(PSD(x)f(x))∑
(PSD(x)) , (***) stands for the centroid frequency com-
puted as spectrum median. The red line is the median value, the edges of
the box are the 75th and 25th percentiles, the red crosses are the outliers.
Double stars (**) indicate statically significant difference, the number near
to the double stars is the p-value.
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(a) Centroid frequency (*) (b) Centroid frequency (***)
(c)
∫
PSD (d)
∫
logPSD2
Figure A.14: P3-C3: alpha band personalization. (*) stands for the centroid frequency
computed as
∑
(PSD(x)f(x))∑
(PSD(x)) , (***) stands for the centroid frequency com-
puted as spectrum median. The red line is the median value, the edges of
the box are the 75th and 25th percentiles, the red crosses are the outliers.
Double stars (**) indicate statically significant difference, the number near
to the double stars is the p-value.
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(a) Centroid frequency (*) (b) Centroid frequency (***)
(c)
∫
PSD (d)
∫
logPSD2
Figure A.15: P4-T4: alpha band personalization. (*) stands for the centroid frequency
computed as
∑
(PSD(x)f(x))∑
(PSD(x)) , (***) stands for the centroid frequency com-
puted as spectrum median. The red line is the median value, the edges of
the box are the 75th and 25th percentiles, the red crosses are the outliers.
Double stars (**) indicate statically significant difference, the number near
to the double stars is the p-value.
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(a) Centroid frequency (*) (b) Centroid frequency (***)
(c)
∫
PSD (d)
∫
logPSD2
Figure A.16: P4-C4: alpha band personalization. (*) stands for the centroid frequency
computed as
∑
(PSD(x)f(x))∑
(PSD(x)) , (***) stands for the centroid frequency com-
puted as spectrum median. The red line is the median value, the edges of
the box are the 75th and 25th percentiles, the red crosses are the outliers.
Double stars (**) indicate statically significant difference, the number near
to the double stars is the p-value.
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A.3 Reactivity index
Eventually, we have computed the variability of the reactivity index and we
have tested if its variability (standard deviation) increases passing from hyper or
eu-glycaemic state to hypoglycaemic one.
We have used the same procedure of chapter 5:
• selection of EEG signal in time domain;
• selection of a series of couples: reference and test time intervals (ri(t), ti(t))
(they last 2 minutes and they distance 10 minutes. The successive couple
(r2(t), t2(t)) is obtained by shifting r1(t) and t2(t) by 0.5 minutes);
• computation of the power spectral density of each couple ((ri(t), ti(t)) →
(Ri(f), Ti(f)));
• computation of the reactivity index for each couple ρi =
∫ fb
fa
Ri(f)−Ti(f)
fb−fa .
• selection of ρ belonging to 1 hour EEG time interval;
These steps were repeated for each subject and for the alpha, theta and beta bands.
For each patient, the 1 hour EEG time intervals were selected from the hypogly-
caemia and then from the euglycaemia period.
The PSD of the couple (ri(t), ti(t)) is obtained by applying the Welch method in
EEG 2 second length epoch with no overlapping.
Moreover, the EEG signal was pre-elaborated for this analysis, we have excluded
EEG values with amplitude greater than 100, because they were surely artifacts.
Then, we have computed the standard deviation of the reactivity indexes and
performed a statistic test with all results from all subjects (in TableA.5).
We can observe the change in varibility of the ρ index in each band from
FigureA.17 to FigureA.20.
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Figure A.17: P3-T3: standard deviation of reactivity index. The red line is the median
value, the edges of the box are the 75th and 25th percentiles, the red
crosses are the outliers. Double stars (**) indicate statically significant
difference, the number near to the double stars is the p-value.
The best results are obtained in theta band: we can notice an increase in
variability passing from hyperglycaemia to hypoglycaemia in all four channels.
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Channel Glycaemic states difference Delta (*) Theta (*) Alpha (*)
Delta (**)
P3-T3 hyper-eu 0 (0.0636) 0 (0.2728) 0 (0.636)
P3-T3 hyper-hypo 0 (0.1671) 1 (7.63 ∗ 10−5) 0 (0.5372)
P3-C3 hyper-eu 0 (0.0636) 0 (0.2047) 0 (0.3546)
P3-C3 hyper-hypo 0 (0.0636) 1 (0.0044) 1 (0.0044)
Channel Glycaemic states difference Delta (*) Theta (*) Alpha (*)
P4-T4 hyper-eu 0 (0.0636) 1 (0.0196) 0 (0.5873)
P4-T4 hyper-hypo 0 (0.1671) 1 (7.62 ∗ 10−5) 1 (0.0044)
P4-C4 hyper-eu 1 (0.0192) 0 (0.0809) 0 (0.1756)
P4-C4 hyper-hypo 0 (0.1671) 1 (0.0192) 0 (0.0636)
Table A.5: Statistic results for ρ variability. In the table, we have reported the results of
the statistics for each channel. 1 stands for statically significant difference, 0
stands for no significant difference between euglycaemic and hypoglycaemic
state. The p-value (likelihood of no difference between glycaemic states) is
in brakets.
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Figure A.18: P3-C3: standard deviation of reactivity index. The red line is the median
value, the edges of the box are the 75th and 25th percentiles, the red
crosses are the outliers. Double stars (**) indicate statically significant
difference, the number near to the double stars is the p-value.
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Figure A.19: P4-T4: standard deviation of reactivity index. The red line is the median
value, the edges of the box are the 75th and 25th percentiles, the red
crosses are the outliers. Double stars (**) indicate statically significant
difference, the number near to the double stars is the p-value.
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(a) Variability in alpha band (b) Variability in theta band
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Figure A.20: P4-C4: standard deviation of reactivity index. The red line is the median
value, the edges of the box are the 75th and 25th percentiles, the red
crosses are the outliers. Double stars (**) indicate statically significant
difference, the number near to the double stars is the p-value.
Thus, the reactivity index appears to be a good indicator to emphasize the difference
between hyper- and hypoglycaemia in theta band.
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